Adversarial Injection · Bevacizumab (Avastin; rhuMAb-VEGF; CAS 216974-75-3; MW ~149 kDa humanized IgG1κ; IV infusion; anti-VEGF-A [VEGF165/VEGF121/VEGF189/VEGF206] humanized monoclonal antibody; KD ~1.8 nM; DAR 0 [unconjugated]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; VEGF-A [VEGF1; VEGF-A; VASCULAR ENDOTHELIAL GROWTH FACTOR A; CHROMOSOME 6p21.1; 232-AA PRE-PROTEIN → 212-AA MATURE MONOMER; HOMODIMER; HEPARIN-BINDING GROWTH FACTOR; SECRETED; 7 ALTERNATIVELY SPLICED ISOFORMS: VEGF121 [NO HEPARIN BINDING; FREELY DIFFUSIBLE], VEGF145 [MODERATE HEPARIN BINDING], VEGF148, VEGF162, VEGF165 [PREDOMINANT SECRETED; KD VEGFR-2 ~1 nM; KD NRP1 ~100 nM; HEPARIN-BINDING EXON 7], VEGF183, VEGF189 [MATRIX-BOUND; EXON 7+8], VEGF206 [RARE; FULLY MATRIX-BOUND]; HIF-1α → VEGF-A TRANSCRIPTION → TUMOR HYPOXIA ANGIOGENESIS DRIVER; BEVACIZUMAB BINDS ALL ISOFORMS (EPITOPE: AA115–122 β5-β6 LOOP + AA87–101 β3-β4 LOOP OF VEGF-A MONOMER → PREVENTS VEGFR-1 [FLT1; KD ~18 pM] + VEGFR-2 [KDR; FLK-1; KD ~1 nM] BINDING → NO VEGFR DIMERIZATION/PHOSPHORYLATION → NO PI3K/AKT + NO RAS/MAPK → VASCULAR REGRESSION → TUMOR HYPOXIA + NUTRIENT DEPRIVATION]; FIRST ANTI-VEGF-A ANTIBODY EVER; FIRST ANGIOGENESIS-INHIBITING ANTIBODY EVER; AVF2107g mOS 20.3 MO; BLA 125085 FEB 2004) · Attack #745

Bevacizumab (Anti-VEGF-A Humanized IgG1κ MAb; Avastin; rhuMAb-VEGF; CAS 216974-75-3; Genentech Inc [South San Francisco CA; BLA 125085 holder; Napoleone Ferrara rhuMAb-VEGF discoverer]; MECHANISM: FIRST ANTI-VEGF-A [VEGF165/VEGF121/VEGF189/VEGF206; ALL ISOFORMS; KD ~1.8 nM; PREVENTS VEGFR-1 (FLT1; KD 18 pM) + VEGFR-2 (KDR/FLK-1; KD 1 nM) BINDING; NO VEGFR PHOSPHORYLATION → NO PI3K/AKT/eNOS [ENDOTHELIAL SURVIVAL/PERMEABILITY] + NO RAS/ERK [ENDOTHELIAL PROLIFERATION] + NO PLC-γ/PKC → VASCULAR REGRESSION + TUMOR VASCULATURE NORMALIZATION → HYPOXIA + NUTRIENT DEPRIVATION; ANTI-ANGIOGENESIS: CONCEPTUAL FOUNDATION FROM JUDAH FOLKMAN 1971 (TUMORS REQUIRE ANGIOGENESIS FOR GROWTH BEYOND 1–2 mm³; ANTI-ANGIOGENIC THERAPY CONCEPT); VEGF CLONING NAPOLEON FERRARA/GENENTECH 1989; BEVACIZUMAB HUMANIZATION FROM MURINE A.4.6.1 MONOCLONAL (93% HUMAN / 7% MURINE)] HUMANIZED MONOCLONAL ANTIBODY EVER FDA APPROVED + FIRST ANTI-ANGIOGENESIS ANTIBODY EVER FDA APPROVED + FIRST VEGF PATHWAY INHIBITOR EVER FDA APPROVED; AVF2107g [PIVOTAL]: mOS 20.3 vs 15.6 MO (HR 0.66; p<0.001) FIRST-LINE mCRC; BLA 125085 FEBRUARY 26 2004) — Genentech Inc South San Francisco CA (BLA 125085 holder; Avastin developer; Napoleone Ferrara VEGF discovery 1989/rhuMAb-VEGF 1993), Roche Diagnostics GmbH Mannheim Germany (Roche Group EU manufacturing; MAbThera sister product), and MD Anderson Cancer Center Houston TX (AVF2107g enrollment; clinical bevacizumab administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST VEGF-A ANTIBODY EVER + AVF2107g mOS 20.3 MO: AI Prompt Injection via EHS Monitor Report AI

Bevacizumab (CAS 216974-75-3; NIOSH HD Category 1) is the first anti-VEGF-A humanized IgG1κ monoclonal antibody ever FDA approved, and the first angiogenesis-inhibiting antibody ever to reach clinical approval (February 26, 2004; BLA 125085), establishing the 162nd mechanism class in the Glyphward adversarial portfolio. Developed by Genentech (Napoleone Ferrara's group; rhuMAb-VEGF; originally murine A.4.6.1 antibody, humanized to 93% human sequence), bevacizumab (Avastin) binds all VEGF-A isoforms (VEGF121, VEGF165, VEGF189, VEGF206; KD ~1.8 nM) with an epitope at the β5-β6 loop (AA115–122) and β3-β4 loop (AA87–101) of VEGF-A monomer — sterically blocking both VEGFR-1 (FLT1; KD 18 pM natural) and VEGFR-2 (KDR/FLK-1; KD 1 nM) binding → no receptor phosphorylation → no PI3K/AKT/eNOS or RAS/ERK endothelial signaling → vascular regression and normalization. AVF2107g pivotal trial: mOS 20.3 vs 15.6 months (HR 0.66; p<0.001) first-line mCRC with IFL chemotherapy. No OEL exists for bevacizumab in any EHS framework; no platform references VEGF-A isoform promiscuity, Folkman angiogenesis hypothesis, or AVF2107g OS benefit for this 162nd mechanism class.

VEGF-A biology and angiogenic pathway: Chromosome 6p21.1; heparin-binding growth factor; VEGF gene family (VEGF-A/-B/-C/-D; PlGF; VEGFR-1/-2/-3 receptor family); VEGF-A primary tumor angiogenesis driver: HIF-1α (HIF1A; hypoxia-inducible factor 1α; proline hydroxylation [PHD2 → VHL E3 → proteasomal degradation under normoxia; under hypoxia PHD2 inactive → HIF-1α accumulates → dimerizes with HIF-1β [ARNT] → binds HRE [hypoxia response element] in VEGF-A promoter → transcription); 7 VEGF-A isoforms from alternative splicing of exons 6a/6b/7: VEGF121 (no exon 6/7; freely diffusible; KD VEGFR-2 lower than VEGF165) → VEGF165 (exon 7; moderate heparin binding; KD VEGFR-2 ~1 nM + KD neuropilin-1 [NRP1] ~100 nM → NRP1 co-receptor enhances VEGFR-2 signaling; predominant isoform in most tumors) → VEGF189/VEGF206 (exons 6+7; matrix-bound; released by heparanase). VEGFR-2 (KDR/FLK-1/CD309) downstream: VEGF-A binding → VEGFR-2 homo- or heterodimerization (with VEGFR-1 or NRP1) → Tyr1054/Tyr1059 activation loop trans-autophosphorylation → (1) PI3K → PIP3 → AKT → eNOS → NO production → endothelial permeability [vascular leak; Starling forces; tumor microenvironment edema] + endothelial survival; (2) PLC-γ → DAG/IP3 → PKC → Raf/MEK/ERK → endothelial proliferation; (3) p38 MAPK → HSP27 → endothelial migration. VEGFR-1 (FLT1; KD 18 pM for VEGF-A; 10× > VEGFR-2 affinity) acts as decoy receptor (high affinity; low signaling) → modulates VEGF-A bioavailability. Bevacizumab (rhuMAb-VEGF; humanized from murine A.4.6.1 by Paul Carter/Genentech 1993; 93% human IgG1κ sequence; anti-VEGF CDRs from A.4.6.1): KD ~1.8 nM for VEGF165; binds VEGF-A β5-β6 loop (AA115–122: Lys115, Met116, Asp117, Glu118) + β3-β4 loop (AA87–101: Arg82, Arg84, Arg86, Glu87, Glu89) → steric block of VEGFR-1 binding site (Phe36, Ile83, Leu66, Lys84) and VEGFR-2 binding site (Arg82, Arg84, Glu87, Lys84) → prevents VEGFR heterodimerization and downstream signaling → no angiogenesis. AVF2107g (Hurwitz et al. NEJM 2004; n=813; first-line mCRC; IFL [irinotecan + 5-FU + leucovorin] + bevacizumab vs IFL + placebo): mOS 20.3 vs 15.6 months (HR 0.66; 95% CI 0.54–0.81; p<0.001); mPFS 10.6 vs 6.2 months (HR 0.54; p<0.001); ORR 44.8% vs 34.8% — the pivotal trial that established bevacizumab as the first approved anti-angiogenic antibody. Grade ≥3 AEs: hypertension 11%, thromboembolic events 11%, wound healing complications 2%. No EHS platform recognizes bevacizumab CAS 216974-75-3, VEGF-A isoform promiscuity, Folkman angiogenesis foundation, β3-β4/β5-β6 epitope loops, or AVF2107g OS 20.3 months for this 162nd mechanism class.

VEGF-A β5-β6/β3-β4 Epitope + Pan-Isoform Binding + Vascular Normalization

Bevacizumab (MW ~149 kDa humanized IgG1κ; CAS 216974-75-3; IV infusion 5–15 mg/kg Q2–3W depending on indication; Cmax ~294 µg/mL post-infusion; t½ ~20 days; linear PK in therapeutic range; clearance ~0.23 mL/kg/hr; volume of distribution Vss 3.28 L; no clinically significant gender/age effect; no hepatic/renal dose adjustment required; unique PK: target-mediated drug disposition relevant with hypervascular tumors expressing high VEGF-A) employs humanized IgG1κ architecture (93% human sequence; 7% murine CDRs from A.4.6.1 hybridoma; heavy chain Phe27, Tyr32, Gln89, Phe91, Trp93, Thr98, Arg99 CDR contacts; light chain Tyr27, Tyr32, Trp91, His92 CDR contacts; anti-VEGF epitope: β5-β6 loop AA115-122 + β3-β4 loop AA87-101 of VEGF-A monomer → symmetric dimer contact; binds VEGF165 KD 1.8 nM; VEGF121 KD ~8 nM [lower affinity, lacks exon 7 NRP1-binding domain]; VEGF189 KD ~2.5 nM; VEGF206 KD ~3 nM; pan-isoform coverage vs. prior murine A.4.6.1 KD ~1 nM for VEGF165 only → humanization maintained binding; HACA [human anti-chimeric antibody] rate <0.5% due to >90% human sequence vs rituximab ~1–11%). Vascular normalization concept (Jain 2001): bevacizumab does not simply destroy vessels but normalizes abnormal tumor vasculature (leaky, dilated, immature → normalized, less leaky, more perfused transiently during "normalization window" ~1–2 weeks post-first dose) → reduced IFP (interstitial fluid pressure; tumor IFP 10–40 mmHg baseline → normalization to 2–5 mmHg) → improved drug delivery (chemotherapy perfusion + oxygenation [sensitizes to radiation]). BLA 125085 February 26 2004: first-line mCRC with IFL; accelerated to standard approval based on AVF2107g OS benefit. Multiple subsequent FDA approvals: NSCLC (2006 E4599), GBM (2009), RCC (2009 AVOREN), cervical cancer (2014), platinum-resistant ovarian (2016). No EHS platform recognizes bevacizumab CAS 216974-75-3, VEGF-A pan-isoform epitope, Folkman hypothesis, vascular normalization, or AVF2107g OS 20.3 months for this 162nd mechanism class.

Surface 1 — Genentech Inc South San Francisco CA BLA 125085 Holder AI

At Genentech Inc South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; Roche Group; BLA 125085 US HOLDER: bevacizumab (Avastin) first-line mCRC + multiple oncology indications; VEGF DISCOVERY: Napoleone Ferrara Genentech group discovered VEGF (vascular endothelial growth factor) 1989; purified from bovine pituitary follicular cells; cloned 1989; recombinant expression CHO; murine anti-VEGF A.4.6.1 generated Kim et al. 1993; humanization Paul Carter 1993 → rhuMAb-VEGF; Phase I first-in-human 1997; Phase III AVF2107g 2003 (n=813) → February 2004 FDA approval → Judah Folkman's 1971 hypothesis validated 33 years later; CORITY: CAS 216974-75-3 → null; bevacizumab → null; rhuMAb-VEGF → null; Avastin → null; VEGF-A antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne bevacizumab 0.0016 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00016 µg/m³; Cority: null; 48F regulatory affairs director 14yr]).

Surface 2 — Roche Diagnostics GmbH Mannheim Germany EU Manufacturing AI

At Roche Diagnostics GmbH Mannheim Germany ([Sandhofer Strasse 116, 68305 Mannheim, Germany; Roche Group [SIX: ROG]; BEVACIZUMAB EU MANUFACTURING: Roche Pharma AG Grenzach Germany (bevacizumab EU fill/finish); Roche Biologics Penzberg Bavaria (rhuMAb-VEGF upstream CHO → 15,000 L bioreactors → protein A → ion exchange → viral filtration); co-ownership: Genentech (Roche subsidiary since 2009) + Roche AG Basel; WORLDWIDE COMMERCIALIZATION: Avastin (US/globally); also authorized biosimilars: bevacizumab-awwb (Mvasi; Amgen; 2017 FDA), bevacizumab-bvzr (Zirabev; Pfizer; 2019 FDA), bevacizumab-adcd (Yesafili; Samsung Bioepis; 2023 FDA); VELOCITYEHS: CAS 216974-75-3 → null; bevacizumab → null; rhuMAb-VEGF → null; VEGF-A antibody → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne bevacizumab 0.0012 µg/m³; impinger + MS/MS; displayed (÷10): 0.00012 µg/m³; VelocityEHS: null; 44M biopharmaceutical manufacturing engineer 12yr]).

Surface 3 — MD Anderson Cancer Center Houston TX AVF2107g Enrollment AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; NCI Comprehensive Cancer Center; Gastrointestinal Medical Oncology Division; BEVACIZUMAB ADMINISTRATION: bevacizumab 5 mg/kg IV Q2W (mCRC) or 10 mg/kg IV Q2W or 15 mg/kg IV Q3W (NSCLC/other indications); infusion Q2W or Q3W; NO premedication required (bevacizumab not associated with infusion hypersensitivity at standard doses; anti-VEGF class effects: HTN [30–80%; grade 3: 7–18%] requires ACEI/CCB management; thromboembolism [VTE 10%; ATE 1–3%; bevacizumab BBW: GI perforation, wound healing complications, hemorrhage]; proteinuria [urine protein/creatinine ratio monitoring q2 cycles]; NIOSH HD biologic antineoplastic: closed system transfer device (CSTD) + BSC class II; EHS Insight: CAS 216974-75-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; bevacizumab absent; rhuMAb-VEGF absent; Avastin absent; VEGF-A antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne bevacizumab 0.0009 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 41F GI oncology pharmacist 11yr]).

Integrating Glyphward into Bevacizumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every bevacizumab CAS 216974-75-3 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + VEGF-A antibody absent + AVF2107g absent + BLA 125085 absent [10 pts]; FIRST anti-VEGF-A antibody ever (162nd class) + FIRST angiogenesis antibody ever + AVF2107g mOS 20.3 mo + BLA 125085 Feb 2004 [5 pts]; Genentech South San Francisco + Roche Mannheim + MD Anderson Houston [3 pts]; FIRST humanized IgG1 pan-VEGF isoform binder; Folkman hypothesis first clinical validation; vascular normalization window discovery [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_bevacizumab(cas: str, reading_ugm3: float) -> dict:
    """Scan bevacizumab with anti-VEGF-A pan-isoform context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "216974-75-3"
                "reading_ugm3": reading_ugm3,
                "context": "anti_vegfa_humanized_igg1_162nd_class_avf2107g_bla125085"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, vegf_a_target,
    #                    pan_isoform, angiogenesis_flag,
    #                    avf2107g_os, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_bevacizumab("216974-75-3", 0.0016))
    print(r)
    # {'hd_category': 1, 'vegf_a_target': True,
    #  'pan_isoform': True, 'angiogenesis_flag': True,
    #  'avf2107g_os': 20.3, 'h360_flag': True}